As we know, the very hopeful looking drug Rintega didn't quite make it to Phase IV but to get to that point it obiously had some pretty good success up to that point and even tremendous success with some patients (http://bit.ly/1rXxLnV). So I checked with maker Celldex to see if it was still available and got this response back --"Ongoing access to rindopepimut has been offered to existing compassionate use recipients, as well as all patients on the rindopepimut arm of the ACT IV study and prior Phase 2 studies. There is a compassionate use program for patients with recurrent glioblastoma based on data previously presented from the Phase 2 ReACT study."
So I'm guessing that new GBM patients like my wife won't have access. If anyone can shed further light on this type of use I'd appreciate it. I'm personally of the belief that if one person has had great success -- why not us.
Some of the vaccine treatment facilities can generate peptide vaccins against EGFRvIII. They can be costly, but that is an option.
ReplyDeleteWhere are these facilities or clinics? Any in USA? thx
ReplyDeleteSorry for the delayed response. There are two that perform excellent work in Europe:
Deletehttp://www.immune-therapy.net/en/praxisgemeinschaft/aerzte.php
http://www.unifontis.net/en/
From what I've heard, they charge $25,000-$40,000
With their vaccines they'll cover more than just EGFRvIII. Vaccine therapy is thought to improve response to immune checkpoint inhibitors if they are needed later.
This group is partly in the US and partly in the Cayman islands, seem too heavy on the marketing to me:
www.perseuspci.com
Jenna,
ReplyDeleteMy neuro oncologist felt important to offer tmz in even unmethylated MGMT patients.
MGMT patients